ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMLN Stock Price » AMLN Stock News

Amylin Pharmaceuticals Share News

 Amylin Pharmaceuticals (mm) Stock Price
AMLN Stock Price
 Amylin Pharmaceuticals (mm) Stock Chart
AMLN Stock Chart
 Amylin Pharmaceuticals (mm) Stock News
AMLN Stock News
 Amylin Pharmaceuticals (mm) Company Information
AMLN Company Information
 Amylin Pharmaceuticals (mm) Stock Trades
AMLN Stock Trades

Bristol-Myers 2nd-Quarter Profit Falls 28% on Drug-Patent Expirations

By Peter Loftus Bristol-Myers Squibb Co.'s (BMY) second-quarter profit declined 28%, as sales were eroded by recent patent expirations for top-selling drugs including the anticlotting pill Plavix. The New York drug maker also lowered its forecast of full-year 2012 earnings. Bristol-Myers plans to get through the patent losses for Plavix and other drugs by boosting sales of newer drugs. The company hopes to bolster its product lineup with its recent agreement to purchase diabetes-drug maker Amylin Pharmaceuticals Inc. (AMLN) for $5.3 billion. In May, Bristol-Myers lost U.S. patent protection for Plavix, which is used to stave off recurrent heart attacks and strokes. This exposed the brand to lower-priced competition from generic versions, and Bristol's second-quarter Plavix sales tumbled 60% to $741 million. Bristol-Myers co-markets the drug with Sanofi (SNY). Another blow was the March loss of patent protection for blood-pressure medications Avapro and Avalide, which pushed combined sales of those drugs down 53% to $117 million. Bristol and other drug makers are in the midst of a wave of patent expirations for blockbuster drugs that have pressured sales. Bristol has had some success bringing new drugs to market to help offset the patent losses, but it also has experienced some research setbacks. For the second quarter, Bristol's profit fell to $645 million, or 38 cents a share, from $902 million, or 52 cents a share, a year earlier. Excluding certain costs such as asset impairments, earnings were 48 cents a share, matching the mean estimate of analysts surveyed by Thomson Reuters. Overall sales declined 18% to $4.44 billion, just ahead of the Thomson mean estimate. U.S. sales dropped 27% to $2.6 billion, while non-U.S. sales fell 1% to $1.9 billion. Although sales for Plavix and the blood-pressure medications declined substantially, sales for other top products increased, ranging from a 1% gain for antipsychotic Abilify to a 71% jump for skin-cancer treatment Yervoy. Bristol-Myers continues to try to bring more drugs to market. One of the most closely watched is Eliquis, an anticlotting drug co-developed with Pfizer Inc. (PFE). The U.S. Food and Drug Administration declined to approve it in June, asking for more information about clinical data. Analysts believe the drug could be a multibillion-dollar seller. Bristol also is developing new drugs for cancer and hepatitis C that have shown promise in studies. The company, however, recently disclosed negative clinical results for experimental liver-cancer drug brivanib. And the FDA has declined to approve the diabetes drug dapagliflozin, developed in partnership with AstraZeneca PLC (AZN). Bristol said Wednesday an advisory committee of the European Union issued a positive opinion on the company's proposed subcutaneous formulation of anti-inflammatory drug Orencia. A European Commission decision is pending. The company lowered its forecast of 2012 earnings to a range of $1.78 to $1.88 a share from a prior range of $1.90 to $2 a share. However, Bristol didn't change its forecast of adjusted earnings, which exclude certain items, of $1.90 to $2 a share. Bristol said the unchanged adjusted earnings forecast factors in the expected three-cents-a-share negative impact related to the planned Amylin acquisition. Write to Peter Loftus at peter.loftus@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Amylin Pharmaceuticals (AMLN)
DateTimeHeadline
08/09/201208:24:09AstraZeneca: Bristol-Myers Squibb Completes Purchase of Amylin
08/02/201212:30:06Bristol-Myers Executive Charged With Insider Trading
08/02/201212:17:26U.S. Charges Bristol-Myers Executive With Insider Trading
08/02/201211:07:11Bristol-Myers Pension Executive Robert Ramnarine Arrested for...
07/26/201210:24:24Evercore 2nd-Quarter Profit Climbs 19% On Higher Investment Banking...
07/25/201208:20:16Bristol-Myers Profit Falls 28%
07/25/201208:00:01Bristol-Myers 2nd-Quarter Profit Falls 28% on Drug-Patent Expirations
07/02/201211:53:36Bristol Sees Commercial Muscle Accelerating Sales of Bydureon
06/29/201223:36:26Bristol-Myers to Buy Amylin Pharmaceuticals for $5.3 Billion
06/10/201220:35:15Novo Nordisk's Victoza More Efficient Than Peers In New Study
06/09/201208:30:11Sanofi's Lantus Cuts Blood Sugar More Than Merck's Januvia in...
06/05/201209:10:47Amylin is Said To Draw First-Round Bids of Up to $29/Share -Bloomberg
04/25/201214:53:05Icahn: Suit Against Amylin Dropped After Talks With CEO
04/19/201213:53:31FDA Is Asked To Remove Novo Nordisk Diabetes Drug From Market
04/09/201213:08:09Icahn Files Lawsuit Against Amylin To Force Nomination Extension
03/28/201210:08:30Amylin Has Rejected $3.5 Billion Buyout Bid By Bristol-Myers...
03/23/201209:08:11Amylin: EU Approves Diabetes Treatment Byetta With Basal Insulin
01/30/201217:42:15US Stocks Edge Lower As Europe's Debt Flashpoints Weigh
01/30/201208:02:33US Stock Futures Lower On Renewed Worries Over Greece
01/27/201216:12:26FDA Approves Amylin's Bydureon Diabetes Drug After Delays

Amylin Pharmaceuticals and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad